CD274 and non-small cell lung carcinoma: In patients with advanced non-small cell lung cancer (NSCLC), especially those with PD-L1 expression ≥ 1%, a pivotal phase 3 trial comparing nivolumab + ipilimumab with chemotherapy revealed a considerably longer overall survival with the immunotherapy combination.